

References

I-30

1. Lipton A, Fizazi K, Stopeck A, et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. *Eur J Cancer*. 2016;53:75-83.
2. Stopeck AT, Fizazi K, Body JJ, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. *Support Care Cancer*. 2016:447-455.
3. Thosani S, Hu MI. Denosumab: a new agent in the management of hypercalcemia of Future *Oncol*. 2015;2865-2871.
4. Prolia (denosumab) injection for subcutaneous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 03/2020.
5. Xgeva (denosumab) injection, for subcutaneous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 06/2020.
6. Shapiro CL, Moriarty JP, Dusetzine S, et al. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). *J Clin Oncol*. 2017; 35:3949-3955.
7. NCCN Drugs & Biologics Compendium™. 2020. National Comprehensive Cancer Network (NCCN).
8. MICROMEDEX®SOLUTIONS Compendia. 2020.
9. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Denosumab. 2020.
10. Deveci MA, Paydas S, Gonlusen G, et al. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases. *Acta Orthopaedica et Traumatologica Turcica*. 2017;51;1-6.
11. Greenblatt MB, Tsai JN, Wein MN. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. *Clinical Chemistry*. 2017;63(2):464-474.

12. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis and Rheumatology*. 2017;69(8):1521-1537.
13. Tu KN, Lie JD, Wan CKV, et al. Osteoporosis: a review of treatment options. *Pharmacy and Therapeutics*. 2018;43(2):92-104.
14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 2020.
15. Barrioneuvo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. *J Clin Endocrinol Metab*. 2019;104(5):1623-1630.
16. Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. *J Clin Endocrinol Metab*. 2020;105(3):587-594.
17. Jeremiah MP, Unwin BK, Greenawald MH, et al. Diagnosis and management of osteoporosis. *Am Fam Physician*. 2015;92(4):261-268.
18. Dhesy-Thind S, Fletcher GG, Blanchette PS, et al: Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. 2017;35(18):2062-2081.
19. Denosumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated [August 26, 2019].
20. Lexi-Drugs. Hudson, OH: Lexicomp, 2020.